Used in research for the treatment of type 2 diabetes, this compound acts as a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). By inhibiting this enzyme, it helps reduce cortisol levels in key tissues such as the liver and adipose tissue, which may improve insulin sensitivity and glucose metabolism. It has been investigated for its potential to lower blood glucose without directly stimulating insulin secretion, making it a candidate for addressing metabolic dysfunction. Studies have focused on its oral bioavailability and tissue-specific activity, supporting its development as part of novel antidiabetic therapies.